Patrick Campbell

A Mayo Clinic-led retrospective analysis suggests patients with T2D had an 88% greater risk of developing any diabetic retinopathy within the first 15 years of diagnosis compared to those with T1D.

Data from a secondary analysis of the PREDICT 1 trial provides insight into the effects of sleep habits on postprandial glucose control among a cohort of healthy individuals.

A study from Emory University details the risk of developing type 2 diabetes among transgender individuals compared to their cisgender counterparts and takes a deeper dive into the influence of gender-affirming hormone therapy on this risk

A systematic review and meta-analysis of phase 3 data on SGLT2 inhibitors in HFpEF suggest the class was associated with a 22% reduction in CV death and hospitalization but found no significant effect on CV death or all-cause mortality as individual end points.

A recent trial found concomitant tricuspid annuloplasty could lower the risk of mortality and progression to severe tricuspid regurgitation among patients with degenerative mitral valve regurgitation.

A recent analysis found patients with diabetes were about 26% less likely to notice symptoms of atrial fibrillation and more likely to experience more comorbidities than their counterparts without diabetes.

An analysis of survey data from patients in multiple countries provides clinicians with an overview of the effects of self-isolation during the COVID-19 pandemic on diabetes management, including access to insulin and blood glucose fluctuations.

An analysis of data from the SPLENDOR study suggests undergoing baraitric surgery was associated with an 88% reduction in risk of progression of fatty liver to cirrhosis, liver cancer, or liver-related death and a 70% reduction in risk of major adverse cardiovascular events in patients with NASH and obesity.

Data from the SWISS-AF study is providing clinicians with insight into the likelihood of patients to perceive symptoms of atrial fibrillation based on whether or not they had diabetes.

A retrospective study leveraging 2-3 years of data found long-term HbA1c control was a greater predictor of COVID-19 severity than a single, contemporary HbA1c measurement as other studies have examined.

Data from the ASCEND trial provide clinicians with insight into the risk of dementia based on long-term use of low-dose aspirin among patients with diabetes and no history of cardiovascular disease.

The most recent analysis from TRANSLATE-HF suggests optimal prescription of dapagliflozin, based on the FDA label, could reduce the risk of mortality and readmission among patients hospitalized for HFrEF.

Data from the Fitbit Heart study presented at AHA 2021 suggest a novel algorithm for detecting irregular heart rhythms had a positive predictive value of 98% for detecting atrial fibrillation in patients with undiagnosed atrial fibrillation.

Viet Le, PA-C, discusses the results of a study he led from AHA 2021 examining 10-year risk of MACE among patients with an LDL-C from 160-189 mg/dL compared to those with an LDL-C below 160 mg/dL.

Deepak Bhatt, MD, MPH, discusses the results of the interim analysis of the REVERSE-IT trial presented at AHA 2021, which indicates bentracimab provided immediate and sustained reversal of ticagrelor's antiplatelet effects in patients requiring urgent surgery or experiencing major bleeding.

After 2 years, there was little difference in cognitive function between patients with nonvalvular atrial fibrillation receiving dabigatran or warfarin in the GIRAF trial, which was presented at AHA 2021.

Deepak Bhatt, MD, MPH, discusses the results of a pooled analysis of the SOLOIST and SCORED trials assessing effects of sotagliflozin based on baseline eGFR among patients included in the trials.

Data from the CRAVE trial, which was presented at AHA 2021, suggests consumption of coffee could impact heart rhythm, daily sleep, and physical activity.

Results from the 6-month analysis of the RAPID CABG trial indicate stopping ticagrelor use 2-3 days prior to CABG was not associated with an increased risk in bleeding compared to discontinuing use 5-7 days prior to surgery.

Results of the AVATAR trial suggest early surgery could reduce the risk of MACE and mortality compared to a conservative treatment approach among patients with severe asymptomatic aortic stenosis and a normal LVEF.

Data presented at ASN Kidney Week 2021 suggests dapagliflozin use was associated with a reduction in the rate of kidney function decline in patients with chronic kidney disease, regardless of whether they have diabetes.

Results of FIDELITY suggest use of finerenone was associated with reductions in risk of all nonfatal kidney end points included in the analysis, regardless of CKD severity.

Data from the CLICK trial presented at Kidney Week 2021 demonstrates chlorthalidone reduced systolic blood pressure by 11 mmHg over a 12-week treatment period among a patient population with stage 4 CKD and uncontrolled hypertension.

An analysis of FIGARO-DKD from Kidney Week 2021 suggests finerenone use was associated with reductions in risk of multiple renal end points, including a 36% reduction in the need for dialysis.

Data from a prespecified analysis of DAPA-CKD presented at Kidney Week 2021 provides insight into the effects of dapagliflozin use on the rate of kidney function decline based on the presence of type 2 diabetes from the trial.

Data from the CLICK trial presented at ASN Kidney Week 2021 suggests the use of chlorthalidone could reduce blood pressure by 11 mmHg among patients with stage 4 chronic kidney disease and poorly controlled hypertension.

Using the Steno Type 1 Risk Engine, a team from Denmark conducted a study suggesting SGLT2 inhibition could lower risk of cardiovascular disease and end-stage kidney disease in patients with type 1 diabetes.

An analysis of secondary end points from FIGARO-DKD presented at Kidney Week 2021 provides further insight into the effects of finerenone on kidney outcomes, including a 36% reduction in need for dialysis.

Results of the 5-year follow-up from SURTAVI, which were presented at TCT 2021, provide insight into the associations of TAVR with mortality and stroke compared to SAVR in patients with severe aortic stenosis considered to be at intermediate risk.

Results of the 6-month follow-up from RADIANCE-HTN TRIO suggest the addition of antihypertensive medications following renal denervation could contribute to further blood pressure lowering in patients with treatment-resistant hypertension.